A Phase 3 trial of Biogen Idec Inc.'s multiple sclerosis treatment BG- 12 met the primary endpoint of reducing the number of patients who relapsed at two years when compared with a placebo.
The investigational oral compound, dimethyl fumarate, also met secondary targets, including lower ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1679